Cochrane · systematic review · CD013714
Probiotics for the prevention of Hirschsprung‐associated enterocolitis
Mei, F, Wu, M, Zhao, L, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 3 · 50%Very low 1 · 16.7%Low 2 · 33.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Probiotics compared to placebo for the prevention of Hirschsprung‐associated enterocolitis
Population: children with Hirschsprung's disease (HD)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Occurrence of HAEC Probiotics vs placebo | OR 0.58 [0.1, 3.43] | 2 studies · 120 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Serious adverse events Probiotics vs placebo | no estimate extracted | 1 study · 60 participants | Ungraded |
Severity of HAEC Â Probiotics vs placebo | OR 0.66 [0.14, 3.16] | 2 studies · 120 participants | Low Downgraded: risk of bias, imprecision |
Overall mortality Probiotics vs placebo | no estimate extracted | 1 study · 60 participants | Ungraded |
Withdrawals due to adverse events Probiotics vs placebo | no estimate extracted | 1 study · 60 participants | Ungraded |
Recurrent episodes of HAEC Probiotics vs placebo | OR 0.85 [0.24, 3] | 1 study · 60 participants | Low Downgraded: risk of bias, imprecision |